Background-Pulmonary vasodilatation with a 100 ppm concentration of NO given as a short burst of a few milliliters at the beginning of each breath (NO min ) was compared with conventionally inhaled NO, in which a full breath of 40 ppm of NO was inhaled (NO CD ). Methods and Results-NO min was studied in 16 patients with severe pulmonary hypertension and in 16 isolated porcine lungs with experimentally induced pulmonary hypertension. We compared volumes of 8 to 38 mL of 100 ppm NO in N 2 injected at the beginning of each breath with conventional inhalation of 40 ppm NO in air. NO CD and NO min were studied in 4 pigs after inhibition of NO synthase with N G -nitro-L-arginine methyl ester (1 to 2 mg/kg IV) had raised the pulmonary vascular resistance index (PVRI) from 4.4Ϯ0. 
I
nhaled NO is a selective pulmonary vasodilator, 1, 2 and in acute respiratory distress syndrome (ARDS), it improves gas exchange. 3 Current methods of administration of NO are complicated and not without hazard. 4 NO is stored in concentrations of 100 to 10 000 ppm, with N 2 . Safe and effective concentrations of inhaled NO range from 1 to 40 ppm, 5 which are achieved by mixing NO with respiratory gases. The flow rate of the mixed gases is carefully matched to the rate of ventilation, preventing buildup of NO 2 . 6 While straightforward for ventilated patients, ambulatory patients who vary their rate of ventilation renders delivery difficult. A new method of delivery is needed for them because inhaled NO can be used to treat pulmonary hypertension. 7 Higher doses of inhaled NO are needed to reduce pulmonary hypertension than to improve gas exchange in ARDS. 8 Conventional delivery (NO CD ), which distributes inhaled NO throughout the lungs, can, however, worsen gas exchange in patients with chronic obstructive pulmonary disease (COPD). 9, 10 Selective delivery of NO to fast-ventilated regions of the lungs could reduce this problem.
An alternative to NO CD is to inject a small volume of NO, added at the start of each breath. This has been learned from measurement of the gas transfer of carbon monoxide (TLCO) and allows NO to reach the resistance pulmonary arteries.
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Methods
Experimentally Induced Pulmonary Hypertension
Sixteen pathogen-free pigs weighing 36 to 60 kg were studied as previously described. 12, 13 Midazolam (0.3 mg/kg IM) and droperidol (0.5 mg/kg IM) premedication was followed by anesthesia with sodium pentobarbital (25 mg/kg IV). They were ventilated (Manley Ventilator, Blease Medical) with 40% O 2 and 60% N 2 , a tidal volume of 10 to 12 mL/kg, and a maximum airway pressure of 10 mm Hg.
In Vivo Porcine Studies
In supine animals, pulmonary artery pressure (PAP), pulmonary wedge pressure (PWP), and right atrial pressure (RAP) in 9 animals, together with right carotid artery pressure (SAP), were measured. Euthanasia was effected immediately at the end with intravenous (10 mL of 1 mol/L) potassium chloride.
Isolated, Perfused Porcine Lung Studies
Isolated, salt-perfused lungs were prepared as previously described 13 through a median sternotomy in 7 pigs. Euthanasia was undertaken by exsanguination. Pulmonary blood flow (Q) was measured with a Doppler flow probe and meter (model 16SB185 and model T101D, Transonic Systems Inc). The RAP, PAP, and left atrial pressure (LAP) were recorded.
The isolated lung was perfused with autologous blood and circulated to the pulmonary artery with a roller pump (model 5001R, Watson Marlow, Manchester). A 150-mL reservoir was interposed between the pump and the pulmonary artery. Perfusion rate of the lungs was slowly increased from 10 to 100 mL Ϫ1 ⅐ min Ϫ1 ⅐ kg Ϫ1 . The lungs were ventilated at a tidal volume of 10 to 12 mL/kg with 20% O 2 , 5% CO 2 , and 75% N 2 .
Methods of NO Delivery
For the NO min , a device 14 delivered a range of volumes of a mixture of 100 ppm NO/N 2 at the beginning of each breath. With a solenoid valve (M8B-3E2C-6DC, Valeader Engineering Ltd), NO/N 2 was released at a flow rate of 12 L/min. The volume of gas and hence the dose delivered depended on the duration of opening times, which ranged from 10 to 1000 ms. This was calibrated before each study with a water spirometer. The valve was manual or automatic and synchronized with the start of inhalation, an automatic function triggered from the airway pressure transducer.
With NO CD , NO was delivered in a gas mixture of 79% N 2 and 21% O 2 (5% CO 2 was added for the isolated lungs) at a concentration of 40 ppm diluted (Pneumopac Ltd) from a mixture of 10 000 ppm NO/N 2 .
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Protocol
Endothelial NO synthase was inhibited with N G -nitro-L-arginine methyl ester (L-NAME) (1 to 2 mg/kg IV; Sigma Chemical Company Ltd). A stable rise of pulmonary vascular resistance index (PVRI) and systemic vascular resistance index (SVRI) occurred 20 to 30 minutes after injection. In the isolated lung studies, to achieve a stable elevation of PVRI after 10 to 15 minutes, the thromboxane analogue U46619 (10 pmol ⅐ L Ϫ1 ⅐ min Ϫ1 , Sigma Chemical Company Ltd) was infused into the isolated lung perfusate. The experiments lasted 120 minutes.
A dose response to increasing concentrations of NO CD was undertaken in 4 animals. Concentrations of 10, 40, and 80 ppm of NO were tested in random order after the PVRI had been increased by L-NAME. Minimal dose of 100 ppm NO/N 2 was tested in 4 pigs after L-NAME infusion. The valve opening time was set at 10, 20, 40, 80, 160, 320, and 1000 ms in random order. The measurements of PVRI were made over a period of 5 minutes.
In 7 isolated lungs, the PVRI after U46619 was reduced by NO CD of 40 ppm NO and NO min with valve opening times set at 10, 80, 160, and 320 ms.
Clinical Study of Severe Pulmonary Hypertension
Sixteen patients with severe pulmonary hypertension were studied. The mean age of the patients was 44.2 (SDϮ13.9) years; 6 had thromboembolic pulmonary hypertension, 8 had unexplained pulmonary hypertension, 1 had pulmonary veno-occlusive disease, and 1 had pulmonary hypertension associated with sarcoidosis. All gave written consent, and the study was approved by the local hospital ethics committee. A diagnostic right heart catheter allowed measurement of mean RAP, mean PAP, and mean PWP.
Methods of NO Delivery
For the NO min , the solenoid switch was operated manually at the start of inhalation. The patient inhaled from a 1-L reservoir bag, through a tightly fitting face mask (Nasal CPAP mask, Puritan-Bennet Corp) fitted with a pneumotachograph and differential manometer giving a record of the breathing pattern (PK Morgan, Maidstone). The reservoir was replenished with 79% N 2 and 21% O 2 (Pneumopac Ltd). For the NO CD , 40 ppm NO was delivered in a gas mixture in 79% N 2 and 21% O 2 to a 1-L reservoir bag from which the patient breathed with the tightly fitted mask.
Protocol
The maximal fall in PVR with the vasodilator intravenous prostacyclin (Epoprostenol, PGI 2 ) 16 was compared with NO CD . For the NO min , the duration of the spike of NO/N 2 (100 ppm) was varied until a minimum dose caused a fall in PVRI of Ն10%. 
Calculations and Statistical Analysis
Results
Porcine Studies
The 10 ppm NO CD was a less effective vasodilator than 40 and 80 ppm of NO CD (Figure 1 ) in 5 animals after L-NAME increased the PVRI by 6.5Ϯ1.1 mm Hg ⅐ mL Ϫ1 ⅐ min Ϫ1 ⅐ kg
Ϫ1
. In 4 animals, L-NAME caused a rise of PVRI from 4.3Ϯ0.8 to 10.0Ϯ1.6 mm Hg ⅐ mL Ϫ1 ⅐ min Ϫ1 ⅐ kg
. The NO min at volumes of 8 to 38 mL produced the same fall in PVRI as did 115 mL ( . The NO CD caused a fall of PVRI to 66.5%, and similar reductions occurred with NO min at volumes of 3 to 38 mL of 100 ppm NO in N 2 ( Figure 2 ). Baseline PVR in response to L-NAME was taken as 100%; reduced PVR is expressed as percentage of this baseline (meanϮSEM). All spiked NO reduced PVR significantly ( PϽ0.01). . Unlike inhaled NO, PGI 2 also caused a fall in SVRI ( Table 2 ). The volumes of gas delivered by the solenoid valve ranged from 3 to 115 mL (Table 1) .
Clinical Study
Discussion
A small volume of NO/N 2 of up to 38 mL, delivered at the beginning of the breath, was as effective a vasodilator as a 40-fold higher dose of NO CD . Conventional delivery required 5.3ϫ10 Ϫ7 to 1.2ϫ10 Ϫ6 mol/L per breath to achieve comparable pulmonary vasodilatation as 1.2ϫ10
Ϫ8 to 1.6ϫ10 Ϫ7 mol/L of the spike.
Pulmonary hypertension is reduced by inhaled NO acting on the precapillary arteries, 12 located anatomically within the pulmonary acini. Inhaled NO must therefore reach the alveolar region at a sufficient concentration. We can learn from the measurement of gas diffusion (TLCO) with carbon monoxide. Being similar to CO, NO is also used to measure diffusion. [17] [18] [19] The use of a small volume of CO added at the start of the inhalation provides an equivalent measure of TLCO. 11 The rate of diffusion of CO (or NO) from this inhaled bolus is slower, for example, 4ϫ10
(400 ppb/min at 37.0°C) 20 than the rate of convective flow of the inhaled air into the lungs, for example, 7500 mL/min. 21 Little change in the concentration of NO (or CO) in the bolus is expected to occur until the alveoli are reached.
The practical advantage of NO min is that the dose of inhaled NO depends on the frequency of breathing, for example, increasing with exercise. With NO CD it is not possible to match the flow rate of the gas mixture of NO to the patient's rate of ventilation unless the patient is supported by a mechanical ventilator. The concentration of NO in the spike never will exceed that in the cylinder. It is not necessary to mix with respiratory gases or to monitor the concentrations of inhaled NO. Furthermore, by comparison with NO CD , slow diffusion from the spike reduces the oxidation of NO to NO 2 , 6 therefore careful monitoring for a buildup of NO 2 4 is not needed.
The delivery of a spike of NO greatly reduces the gas waste compared with continuous inhalation, in which 50% of the gas is lost during expiration. We estimate that for a 10-mL spike of NO/N 2 to be delivered, in each breath only 216 L of NO/N 2 would be needed each day. A small container the size of a hip flask could be easily carried by the patient, considerably reducing the daily volume of gas needed to treat primary pulmonary hypertension. 7 The lowest effective vasodilatory concentration of inhaled NO remains to be determined. The NO CD systems give concentrations of NO in the inspirate of 1 to 120 ppm. 22 To relax pulmonary arteries in vitro requires 2 ppm of NO gas. 23 Most of the inhaled NO combines with oxyhemoglobin of red blood cells to form methamoglobin. 24 This indicates a considerable redundancy in the NO CD dose.
Finally, by inhaling NO as a bolus at the beginning of inspiration, it is distributed only to fast-ventilated regions of the lungs. 25 Slow-filling lung units will receive less NO than with NO CD . This should avoid the worsening gas exchange in COPD seen with NO CD , 9,10 as with inhaled bronchodilators. 25 This could extend treatment with inhaled NO to patients with COPD.
In summary, we describe a means of reducing the effective dose per breath of NO by 40-fold when compared with conventional delivery and that lessens potential toxicity 26 as well as offering a safe means of treating ambulatory patients. It should overcome the problems of worsening V A /Q inhomogeneity, to allow inhaled NO to be used for COPD. 
